The studies have described a complex relationship between schizophrenia and alcohol consumption. On the other hand, they consider chronic alcohol consumption to cause psychotic symptoms (alcohol-induced hallucinosis). Distinguishing these symptoms from schizophrenia is difficult, similar to methamphetamine or other stimulant use. Recent studies have shown higher consumption of alcohol and drugs in these populations (
15,
16). In a study conducted by Zai et al. in Toronto, Canada, in 2018, the prevalence of alcohol use disorder in schizophrenia patients was over 20%. In our study, the prevalence of lifetime alcohol use in individuals with schizophrenia was 45.5%, followed by low-risk consumption (23%), high-risk alcohol consumption (10%), and alcoholism (1.5%) based on the AUDIT questionnaire (
8).
In another study published by Moggi in Germany in 2018, nearly half of the patients with schizophrenia had comorbidity with substance use disorder, and about a third of them also had alcohol use disorder. In comparison, our study showed that 44% of schizophrenic patients had a history of any substance use; this rate was higher in individuals with lifetime alcohol use (60%), and more than 62% of this population had a history of cigarette smoking. If we just consider the male population in this regard, the cigarette smoking rate was more than 80% (
17).
In a meta-analysis study published in Australia by Hunt et al. in 2018, information on the prevalence of concurrent drug and alcohol use in schizophrenia patients was extracted from 1990 to 2017. According to the findings, more than 24% of the population had comorbid alcohol. In our study, the prevalence of lifetime alcohol use was higher, almost equal to the rate of low-risk alcohol consumption, while the rates of high-risk alcohol consumption and alcoholism were lower (
18).
In another study published in Singapore, East Asia, by Subramaniam et al. in 2017, the prevalence of problematic alcohol consumption in the population with schizophrenia and depression was investigated. The results of this study indicated that the prevalence of high-risk alcohol consumption was about 12%. This number was about 18% for people with depression and 6% for people with schizophrenia (
19). According to the results of the above study, the prevalence of high-risk alcohol consumption in eastern societies, especially in people with schizophrenia, was significantly lower than the results obtained in the studies of western countries. It was even significantly lower than our study results in the Middle East (
20). The aldehyde dehydrogenase 2 deficiency possibly plays a role in reducing alcohol consumption in the eastern population.
The largest study published by the National Center for Addiction Studies in Tehran by Amin-Esmaeili et al. in 2017 investigated the prevalence of alcohol consumption in 7,840 people aged 15 to 64. According to the results, the prevalence of alcohol consumption was about 1%, and harmful consumption was estimated at 0.6%. This statistic is significantly lower than the statistics of East Asian countries. Our study showed that the prevalence of lifetime alcohol consumption and problematic alcohol use was much higher in individuals with schizophrenia than in the general population in Iran (
21).
The results of a study published by Habibisaravi et al. in 2015 at Zare Psychiatry Hospital in Sari showed a high prevalence of drug use in hospitalized psychiatric patients, in which opioids alone or with other substances were the most commonly used substances in patients. In that study, the lifetime consumption of alcohol was mentioned in about 9% of psychiatric patients, which is much lower than in our study (
22). This finding can be explained by increasing alcohol consumption after the COVID-19 pandemic because of a misconception in society that alcohol consumption has a protective role against the coronavirus.
The other study by Nikfarjam et al. in 2017 investigated alcohol consumption in the Iranian population using the Network Scale-up (NSU) method. The results of this study indicated that the prevalence of alcohol consumption in the past year was about 2.31% in men, which was eight times higher in men than in women. It was about three times higher in the population under 30 years old than in the population over 30 years old. In our study, the highest percentage of alcohol use was in the third decade of life, and it was significantly higher in the male population. The percentage of alcohol use, whether lifetime or harmful, was much higher than in the general population mentioned in this study (
23).
In another study by Ahmadi et al. in 2001 in Shiraz, 205 psychiatric inpatients were examined for drug use. According to this study, schizophrenia patients constituted more than 61% of current drug users. The prevalence of alcohol consumption was reported as high as 23% in men and 4% in hospitalized women. Compared with our study regarding gender, almost 43% of the male population had a history of lifetime alcohol use. Compared with the female population, this percentage was 8%. Regarding low-risk alcohol use, the rate in the male population was about 30%, while in the female population, it was 4%. The rate of high-risk alcohol consumption was 12% in the male population and 4% in the female population, and finally, the percentage of alcoholism was 2% in the male population and zero in females (
24).
Eventually, our study showed a higher rate of lifetime alcohol use, low-risk alcohol use, high-risk alcohol use, and alcoholism in schizophrenia patients than in the general population, as approved in similar studies conducted in Western countries. The results of our study in the Middle East regarding alcohol use in schizophrenia are more similar to those of Western countries than eastern countries. The ratio of alcohol use in schizophrenia compared with the general population in our study was even higher than this ratio in Western countries.
Considering the result of this study, alcohol use in a particular population, such as psychiatric patients, especially with schizophrenia, should be more considered.
As a result of disorganization and negative symptoms of schizophrenia, they usually do not tend to explain their problems to psychiatrists or other healthcare providers. Hence, mental healthcare providers such as psychologists and psychiatrists must consider these issues to prevent more severe medical and psychological complications.